The cancer biologics market comprises biological products such as monoclonal antibodies, vaccines, cell therapies, and gene therapies used in the prevention, diagnosis, and treatment of various types of cancer. Cancer biologics have emerged as promising therapeutic options due to their high specificity and ability to induce few side effects compared to conventional chemotherapy. Monoclonal antibodies play a crucial role and are widely used either alone or combined with other therapeutic agents to treat several cancers, including breast, lung, colorectal, and blood cancers. Extensive research on targeted therapies and new drug developments is expected to boost the demand for cancer biologics.

The Global Cancer Biologics Market is estimated to be valued at US$ 108.87 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the Cancer Biologics Market are F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc., Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., and Johnson & Johnson Services, Inc. These players are actively investing in R&D to develop new and improved cancer biologics.

Rising prevalence of cancer worldwide due to changing lifestyles and growing geriatric population is a major factor fueling the demand for cancer biologics. According to the International Agency for Research on Cancer, the number of new cancer cases per year is projected to rise from 18.1 million in 2018 to 29.5 million by 2040.

Advances in biotechnology have enabled development of novel cancer biologics with greater efficacy and improved specificity. Ongoing preclinical and clinical research on cell and gene therapies holds promise to revolutionize cancer treatment. CAR-T cell therapy has shown remarkable success in treatment of blood cancers.

Market Trends
Increasing personalized medicine approach- Advances in precision medicine and companion diagnostics are enabling development of targeted cancer biologics based on patient's genetic makeup and tumor mutations. This trend of precision oncology is gaining adoption.
Rising focus on combination therapies- Combination of cancer biologics with chemotherapeutics, targeted therapies or immunotherapies is demonstrating improved efficacy. Many large players are evaluating drug combinations in clinical trials.

Market Opportunities
Emerging economies in Asia Pacific and Latin America present lucrative opportunities for cancer biologics market players due to growing healthcare investments, increasing cancer burden and large patient pools in these regions.
Significant opportunities exist for development of novel cancer vaccines and cell therapies as these areas have seen limited approvals and commercial success to date. Efforts are ongoing to address fabrication challenges and improve effectiveness of these therapies.

Impact of COVID-19 on Cancer Biologics Market

The COVID-19 pandemic has impacted the growth of the cancer biologics market as patients temporarily delayed non-emergency treatments and clinical trials. During the peak, the number of cancer screenings declined significantly due to concerns over exposure to the virus and focus being diverted towards treating COVID-19 patients. This has led to late detection and diagnosis of new cancer cases post the pandemic. The lockdowns and social distancing norms also disrupted the supply chains, manufacturing and distribution of cancer biologics initially. However, in late 2020, the market started stabilizing as healthcare systems adapted to the new normal. Companies are now focusing on expanding access to treatments through telehealth and homecare. Governments and private organizations have also accelerated efforts to develop novel vaccines and therapies for cancer patients. They aim to minimize treatment disruptions and reduce cancer mortality in the coming years through strategic policies.

In terms of geographical concentration, North America accounts for the largest share in the cancer biologics market currently in terms of value. This is attributed to factors such as rising cancer incidence, growing awareness, established healthcare infrastructure and favorable reimbursements. Within the region, United States dominates owing to presence of key market players and high spending on cancer research. However, Asia Pacific is projected to be the fastest growing market during the forecast period. This can be credited to increasing healthcare investments, expansion of medical facilities and rising disposable incomes in developing countries like India, China and South Korea. Governments are encouraging development of indigenous biopharma capabilities in the region.

With focus on new treatments and continued R&D, the cancer biologics market is anticipated to expand despite the impact of the pandemic. Successful vaccination programs worldwide will help in improving access to uninterrupted care. Companies should continue collaborating with health authorities to meet the evolving demands of cancer patients.

Geographical Regions

Asia Pacific is projected to be the fastest growing region for the Cancer Biologics Market during the forecast period. This can be attributed to factors such as the rising incidences of cancer, growing healthcare expenditures, increasing disposable incomes, expanding medical infrastructure and focus on indigenous manufacturing capabilities in emerging countries like India, China and South Korea. Governments in the region are implementing supportive policies and incentives to attract biopharma investments. For instance, China aims to develop a US$ 150 billion biosimilars industry by 2035 through various initiatives. In addition, diseases burden coupled with large patient pool offers huge market potential in Asia Pacific for cancer drugs developed through advanced biotechnology.

 

Get more insights on this topic:

https://www.dailyprbulletin.com/cancer-biologics-market-regional/